Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
Guanxuanzi Zhang, Na Zhang, Juan Xu...
https://pubmed.ncbi.nlm.nih.gov/37543121Actively Recruiting
Phase 4
Age: 18Years +
All Genders
ID06637332
DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Led by Todd C. Lee MD MPH FIDSA · Updated on 2026-05-26
300
Participants Needed
16
Research Sites
43 weeks
Total Duration
On this page
Sponsors
T
Todd C. Lee MD MPH FIDSA
Lead Sponsor
U
University of Melbourne
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating and directly comparing the two most commonly used therapies, vancomycin and daptomycin, for patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections. This open-label randomized controlled trial is a sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial, aiming to understand which treatment may provide better outcomes for this serious infection. Participants will receive either daptomycin or vancomycin by injection. Daptomycin will be given at a dose determined by the treating clinicians but not less than 6 mg/kg. Vancomycin dosing will be managed to meet specific trough or area-under-the-curve (AUC) targets based on local standards. The treatment period and monitoring align with the SNAP trial protocols. During the study, participants will be monitored up to 90 days after enrollment for outcomes including a Desirability of Outcome Ranking (DOOR), clinical failure, adverse events leading to treatment discontinuation, mortality, infectious complications, and specific drug-related side effects like myositis and eosinophilic pneumonia. Safety and treatment effectiveness measures will be collected and evaluated as part of the trial's follow-up.
CONDITIONS
Brief Title
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Diagnosis of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia
- Meet all inclusion and exclusion criteria of the SNAP Platform trial (NCT05137119)
You will not qualify if you...
- Severe allergy or non-severe rash to vancomycin or daptomycin
- Suspected or confirmed MRSA pneumonia
- Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L
- Known daptomycin minimum inhibitory concentration (MIC) greater than or equal to 1mg/L
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 42 days from enrollment
Participants receive either Daptomycin or Vancomycin by injection as determined by the treating clinicians to treat MRSA bacteremia.
Multiple visits during treatment as determined by clinical care
Follow-up
Duration - Up to 90 days post enrollment
Participants are monitored for outcomes such as clinical failure, adverse events, and mortality after treatment ends.
Periodic follow-up visits up to 90 days
Trial Site Locations
Total: 16 locations
1
Concord Repatriation and General Hospital
Concord, New South Wales, Australia, 2139
Actively Recruiting
2
John Hunter Hospital
Newcastle, New South Wales, Australia, 2305
Actively Recruiting
3
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Actively Recruiting
4
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia, 4029
Actively Recruiting
5
Flinders Medical Centre
Bedford Park, South Australia, Australia, 5042
Actively Recruiting
6
Box Hill Hospital
Box Hill, Victoria, Australia, 3128
Actively Recruiting
7
Monash Medical Campus (Monash Medical Centre + Jesse McPherson Private Hospital)
Clayton, Victoria, Australia, 3168
Actively Recruiting
8
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Actively Recruiting
9
Fiona Stanley Hospital
Murdoch, Western Australia, Australia, 6150
Actively Recruiting
10
Royal Perth Hospital
Perth, Western Australia, Australia, 6000
Actively Recruiting
11
University of Alberta Hospital
Edmonton, Alberta, Canada
Actively Recruiting
12
Fraser Health Authority (Surrey Memorial Hospital)
Surrey, British Columbia, Canada, V3V1Z2
Actively Recruiting
13
Newfoundland Health Services (Health Sciences Centre and St. Clare's Mercy Hospital)
St. John's, Newfoundland and Labrador, Canada
Actively Recruiting
14
Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital)
Hamilton, Ontario, Canada, L8L 2X2
Actively Recruiting
15
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
16
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
Montreal, Quebec, Canada, H4A3S1
Actively Recruiting
Loading map...
Research Team
L
Lina Petrella
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Vance G Fowler, Helen W Boucher, G Ralph Corey...
https://pubmed.ncbi.nlm.nih.gov/16914701